Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Aristides D Tagalakis"'
Autor:
Maria D I Manunta, Robin J McAnulty, Aristides D Tagalakis, Stephen E Bottoms, Frederick Campbell, Helen C Hailes, Alethea B Tabor, Geoffrey J Laurent, Christopher O'Callaghan, Stephen L Hart
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26768 (2011)
Gene therapy mediated by synthetic vectors may provide opportunities for new treatments for cystic fibrosis (CF) via aerosolisation. Vectors for CF must transfect the airway epithelium efficiently and not cause inflammation so they are suitable for r
Externí odkaz:
https://doaj.org/article/b4e704dda6444ec3ac8d0e904dd593d2
Autor:
Jinyuan Luo, Greymi Tan, Kai Xin Thong, Konstantinos N. Kafetzis, Neeru Vallabh, Carl M. Sheridan, Yusuke Sato, Hideyoshi Harashima, Aristides D. Tagalakis, Cynthia Yu-Wai-Man
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2472 (2022)
The primary cause of failure for minimally invasive glaucoma surgery (MIGS) is fibrosis in the trabecular meshwork (TM) that regulates the outflow of aqueous humour, and no anti-fibrotic drug is available for intraocular use in MIGS. The myocardin-re
Externí odkaz:
https://doaj.org/article/f81134b72765434d8df5ccafcd8d7fdb
Autor:
Nicole Ioannou, Jinyuan Luo, Mengqi Qin, Matteo Di Luca, Essyrose Mathew, Aristides D Tagalakis, Dimitrios A Lamprou, Cynthia Yu-Wai-Man
Publikováno v:
Ioannou, N, Luo, J, Qin, M, Di Luca, M, Mathew, E, Tagalakis, A D, Lamprou, D A & Yu-Wai-Man, C 2023, ' 3D-printed long-acting 5-fluorouracil implant to prevent conjunctival fibrosis in glaucoma ', Journal of Pharmacy and Pharmacology, vol. 75, no. 2, pp. 276-286 . https://doi.org/10.1093/jpp/rgac100
Objectives To develop a sustained release 5-fluorouracil (5-FU) implant by three-dimensional (3D) printing to effectively prevent conjunctival fibrosis after glaucoma surgery. Methods 3D-printed implants composed of polycaprolactone (PCL) and chitosa
Autor:
Dania Grant-Serroukh, Morag R. Hunter, Ruhina Maeshima, Aristides D. Tagalakis, Ahmad M. Aldossary, Nour Allahham, Gareth R. Williams, Mark Edbrooke, Arpan Desai, Stephen L. Hart
Publikováno v:
Journal of Controlled Release. 348:786-797
Despite recent advances in the field of mRNA therapy, the lack of safe and efficacious delivery vehicles with pharmaceutically developable properties remains a major limitation. Here, we describe the systematic optimisation of lipid-peptide nanocompl
Autor:
Cynthia Yu-Wai-Man, Nicholas Owen, Jonathan Lees, Aristides D. Tagalakis, Stephen L. Hart, Andrew R. Webster, Christine A. Orengo, Peng T. Khaw
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract Fibrosis-related events play a part in most blinding diseases worldwide. However, little is known about the mechanisms driving this complex multifactorial disease. Here we have carried out the first genome-wide RNA-Sequencing study in human
Externí odkaz:
https://doaj.org/article/5c0371687dca468ab80f8f19c7cf2ac1
Autor:
Maria D. I. Manunta, Aristides D. Tagalakis, Martin Attwood, Ahmad M. Aldossary, Josephine L. Barnes, Mustafa M. Munye, Alexander Weng, Robin J McAnulty, Stephen L. Hart
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract The inhibition of ENaC may have therapeutic potential in CF airways by reducing sodium hyperabsorption, restoring lung epithelial surface fluid levels, airway hydration and mucociliary function. The challenge has been to deliver siRNA to the
Externí odkaz:
https://doaj.org/article/e1dcd0da9f604c4c97453b6b34085cf2
Autor:
Konstantinos N. Kafetzis, Natalia Papalamprou, Elisha McNulty, Kai X. Thong, Yusuke Sato, Aleksandr Mironov, Atul Purohit, Philip J. Welsby, Hideyoshi Harashima, Cynthia Yu‐Wai‐Man, Aristides D. Tagalakis
Publikováno v:
Advanced Healthcare Materials. :2203022
Autor:
Elsa Irving, Simon Eaton, Ari Lehtonen, Stephen L. Hart, Ruhina Maeshima, Andrew W. Stoker, Aristides D. Tagalakis
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Scientific Reports
Scientific Reports
Oxidovanadium complexes with organic ligands are well known to have cytotoxic or differentiating capabilities against a range of cancer cell types. Their limited use in clinical testing though has resulted largely from uncertainties about the long-te
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports
Scientific Reports
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regula
Autor:
Greymi Tan, Nicole Ioannou, Essyrose Mathew, Aristides D. Tagalakis, Dimitrios A. Lamprou, Cynthia Yu-Wai-Man
Publikováno v:
Tan, G, Ioannou, N, Mathew, E, Tagalakis, A D, Lamprou, D A & Yu-Wai-Man, C 2022, ' 3D printing in ophthalmology: from medical implants to personalised medicine ', International Journal of Pharmaceutics, vol. 625, 122094 . https://doi.org/10.1016/j.ijpharm.2022.122094
3D printing was invented thirty years ago. However, its application in healthcare became prominent only in recent years to provide solutions for drug delivery and clinical challenges, and is constantly evolving. This cost-efficient technique utilises